This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cencora Rallies 14.7% Year to Date: What's Driving the Stock?
by Zacks Equity Research
COR is gaining traction from the robust U.S. Healthcare Solutions segment, which raises optimism about the stock.
Henry Schein Stock Gains From Dental Business Expansion Amid Macro Woe
by Zacks Equity Research
Henry Schein strategically sets up distribution centers worldwide to better serve customers and increase its operating efficiency.
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
by Zacks Equity Research
Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
by Zacks Equity Research
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
BRKR Stock to Gain From Newly Formed Bruker Spatial Biology Division
by Zacks Equity Research
Bruker announces the formation of the new Bruker Spatial Biology division.
Encompass Health Corporation (EHC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
DaVita HealthCare (DVA) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the most recent trading session, DaVita HealthCare (DVA) closed at $164.82, indicating a +0.15% shift from the previous trading day.
Catalent Stock Flat Following the Sell Agreement With Ardena
by Zacks Equity Research
CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.
HealthEquity Gains 28.3% YTD: What's Driving the Stock?
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Acadia Healthcare Ventures in South Carolina With Three Buyouts
by Zacks Equity Research
ACHC expands its CTC network by acquiring three opioid treatment program clinics in South Carolina.
Centene's Meridian Unit Wins Michigan Contract for HIDE SNP Plan
by Zacks Equity Research
CNC's Meridian subsidiary secures a contract to provide integrated Medicare and Medicaid services in Michigan through a new HIDE SNP program, which is expected to boost its member base and statewide presence.
Can DaVita Stock Continue Its Bull Run After Doubling in a Year?
by Indrajit Bandyopadhyay
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.
DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Reasons to Retain PacBio Stock in Your Portfolio for Now
by Zacks Equity Research
PACB's strong product demand and continued focus on R&D raise optimism about the stock.
SNN Stock May Gain Following the Co-Marketing Deal With JointVue
by Zacks Equity Research
Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.
BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research
by Zacks Equity Research
BD aims to automate the complex library preparation process to aid researchers get consistent results and minimize the variability stemming from manual procedures.
SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device
by Zacks Equity Research
SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.
Are Investors Undervaluing DaVita (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita HealthCare (DVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw DaVita HealthCare (DVA) settling at $159.43, representing a +0.08% change from its previous close.
Here's Why You Should Add Elevance Health Stock to Your Portfolio
by Zacks Equity Research
ELV benefits from an increase in employer group fee-based memberships, partially offsetting the impact of Medicaid memberships.
DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?
by Zacks Equity Research
DVA's strong performance and growth strategies, including patient-centric care and international expansion, position it well for continued success despite potential risks.
AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery
by Zacks Equity Research
AMN Healthcare aims to enhance staffing efficiency and improve operational efficiency in healthcare systems via the latest launch.
Here's Why You Should Add DaVita Stock to Your Portfolio Now
by Zacks Equity Research
DVA's strength in its kidney care business raises optimism about the stock.